The HPV South Asia Meeting, held in December 2022 in New Delhi, opened with warm welcomes from Prof. Narendra Kumar Arora (INCLEN, Delhi) and Prof. Alex Vorsters (University of Antwerp), representing the CHIC SPC and the HPV Prevention and Control Board.Prof. Neerja Bhatla (AIIMS, New Delhi) and Dr. Prashant Mathur (NCDIR-ICMR, Bengaluru) delivered the opening […]
Symposium ID: Delhi2022
Welcome Note – Day 3
The session reviewed South Asia’s HPV vaccination efforts within the WHO 90-70-90 strategy, noting five countries with national programs and two with subnational rollouts. Lessons from Sri Lanka, India, and Pakistan highlighted integration with adolescent health schemes, training, and media engagement. Challenges included vaccine supply, funding, and sociocultural barriers, particularly consent and awareness. WHO updates […]
Welcome Note – Day 2
The summary covered topics from the first day of the symposium, focusing on the regional HPV cancer burden and highlighting inequities in incidence, outcomes, and risk factors across South Asia. Cervical cancer was framed as both a medical and social disease closely linked to poverty, with challenges such as late detection, economic strain on families, […]
Cancer registries – data collection, challenges and steps to strengthen registries and improve cervical cancer data collection – India
Dr. Prashant Mathur (India) presented cancer registry data from India, highlighting trends in HPV-related cancers and the challenges of incomplete national coverage. He emphasized the rising burden of cervical cancer in specific high‑incidence states and the need to strengthen population‑based registries for accurate monitoring. The presentation underscored gaps in mortality reporting and disparities between urban […]
Update on one dose trial data findings Single-dose HPV Vaccination Efficacy among adolescent girls and young women in Kenya – KEN SHE trial
Groundbreaking evidence from Kenya demonstrates >97% efficacy of a single-dose HPV vaccine (bivalent and nonavalent) against HPV 16/18 infections over 18 months.The trial also showed ~89% protection against additional high-risk HPV types (31/33/45/52/58), reinforcing its broad preventive impact.This randomized, double-blind study enrolled 2,275 young women (15–20 years), maintaining high retention and protocol fidelity.No vaccine-related serious […]
Costa Rica HPV Vaccine Trials
Costa Rica’s landmark HPV trials continue to provide long-term data on single-dose efficacy and durability.Initial findings show >80% protection against HPV 16/18 infections sustained 10+ years after one dose—comparable to three doses.The ongoing ESCUDDO trial (20,000 girls) is testing non-inferiority of one vs. two doses, with results expected to guide future global policy.Primavera and Prisma […]
Single dose HPV vaccine trials in India
The India IARC trial evaluated HPV vaccination regimens among 20,000 girls aged 10–18. Initially designed to compare two- versus three-dose schedules, program suspension led to observational analysis of one-, two-, and three-dose cohorts. Over 10 years, single-dose recipients demonstrated robust, sustained immune responses against HPV 16/18, with stable antibody levels and comparable efficacy to multi-dose […]
Update on one dose trial data findings – Q&A Session
The panel reviewed evidence from multiple single-dose HPV vaccine studies, including India IARC, Costa Rica, Doris, and Kenshe trials. Observational and randomized data consistently show robust, durable immune responses and high efficacy of single-dose schedules, particularly against HPV 16/18. Immune responses remain stable over a decade, comparable to two- or three-dose regimens. Ongoing studies (Escudo, […]
WHO position paper on new recommendation and Global overview on HPV vaccine efficacy and safety
Paul Bloem (WHO/IVB) presented evidence on HPV vaccine efficacy, safety, and updated WHO recommendations. He underscored >90% protection against HPV 16/18 and herd effects at high coverage. Long-term studies show stable antibody levels over 10+ years for 1, 2, and 3 doses, with single-dose trials demonstrating ~97% efficacy against persistent infection. These findings informed WHO’s […]
WHO position paper on new recommendation and Global overview on HPV vaccine efficacy and safety – Q&A Session
The Q&A session addressed community concerns on HPV vaccine safety, duration of protection, and gender equity in vaccination. Questions covered reported adverse events (e.g., seizures, headaches, menstrual symptoms), long-term antibody persistence, and the relevance of early cancer incidence in efficacy studies. Paul Bloem clarified that extensive global safety reviews show no causal links between HPV […]